peptides for injury recovery: Frequently asked questions

Peptides accelerate existing healing processes. They don't replace them. If baseline tissue repair isn't occurring (due to poor vascularization, nutritional deficiency, or chronic inflammation), peptides have limited substrate to work with. Verify adequate protein intake (1.6–2.2 g/kg body weight daily), sufficient sleep (7–9 hours), and absence of systemic inflammation (elevated CRP or ESR). If recovery remains stalled after 3–4 weeks despite peptide use and proper rehabilitation, the injury may require imaging (MRI or ultrasound) to rule out complete tendon rupture, avascular necrosis, or other structural damage that peptides can't address.

Most peptide research protocols begin administration after the acute inflammatory phase subsides (72+ hours post-injury), during the proliferative phase when fibroblast activity peaks. Administering peptides like BPC-157 during peak inflammation may theoretically blunt the body's natural inflammatory signaling, which is necessary for debris clearance and macrophage recruitment. Wait until swelling stabilizes and the injury site transitions from the inflammatory to the repair phase before starting peptide administration. Typically 3–5 days post-injury for soft tissue, longer for bone.

Discard the vial immediately. Don't attempt to salvage it by refrigerating afterward. Once amino acid oxidation begins at ambient temperature (18–25°C), the structural degradation is irreversible and continues even after re-cooling. A peptide left out for 8+ hours has undergone enough conformational change that receptor binding affinity drops by 70–90%, rendering it biologically inert. There's no home test to verify potency. The only responsible action is disposal and replacement.

Start TB-500 instead. BPC-157's angiogenic effects are most pronounced during the inflammatory phase (0–5 days) when VEGFR-2 expression peaks. After day 7, vascular proliferation is already underway, and adding BPC-157 provides diminishing benefit. TB-500 remains effective through day 21 because fibroblast activity and collagen deposition continue throughout proliferation. If the injury is in the remodeling phase (beyond week 3), GHK-Cu is the appropriate peptide. It targets collagen remodeling and scar tissue refinement, which occur during weeks 3–12.

A plateau typically signals transition from proliferation to remodeling. The cellular processes driving early recovery (angiogenesis, fibroblast infiltration) have completed, and collagen turnover becomes the rate-limiting step. This is when GHK-Cu becomes most effective. Continuing BPC-157 or TB-500 beyond day 21 provides minimal additional benefit because their target pathways are no longer active. Plateaus can also indicate inadequate mechanical loading. Collagen alignment requires controlled stress during remodeling, which is why physical therapy protocols emphasize progressive loading starting at week 4–6.

Discard it immediately. Cloudiness or discoloration indicates protein aggregation or bacterial contamination. Both render the peptide ineffective and potentially unsafe. Properly reconstituted peptides should appear clear and colorless. Aggregation occurs when peptides are stored above 8°C or reconstituted with non-sterile water. Once protein structure denatures, bioavailability drops to near zero. Injecting aggregated peptide delivers no therapeutic benefit. Always reconstitute with bacteriostatic water, store at 2–8°C, and inspect visually before every administration.

Administer the missed dose as soon as you remember if fewer than 12 hours have passed since the scheduled time, then resume your regular schedule. If more than 12 hours have passed, skip the missed dose and continue with the next scheduled injection. Do not double-dose. Missing one or two doses during a 4–6 week protocol has minimal impact on overall recovery, but consistent daily dosing during the acute inflammatory phase (first 10 days post-injury) maximizes fibroblast recruitment when tissue remodeling is most active.

Expel the air immediately by tilting the vial upright and gently tapping to collect the air bubble at the top, then push it out through the needle before withdrawing the plunger. Excess air creates positive pressure inside the vial, which can force contaminants backward through the needle on subsequent draws. This is the hidden contamination vector most protocols ignore. If air remains trapped after reconstitution, the vial is still usable, but draw carefully to avoid aspirating the air pocket into your syringe.

Chronic injuries beyond six weeks often require TB-500 addition to restart stalled collagen remodeling. BPC-157 alone may not address the vascular insufficiency limiting nutrient delivery to the injury site. Add TB-500 at 5mg loading dose (two injections in week one), then 2mg twice weekly maintenance while continuing BPC-157 at 250–500mcg daily. If no improvement appears after four weeks on combined protocol, the injury may involve structural damage (complete tendon rupture, bone involvement) that peptides cannot address without surgical intervention.